Imidazoquinoline Resiquimod (R-848)

Fig-1: Chemical structure of Imidazoquinoline Resiquimod (R-848)

Roll over image to zoom in

Product code: 15-1016

Application :	Functional Assay

Shipping Info:

Order now and get it on Friday July 04, 2025

Download TDS / Manual

Write a review for this product on BioCompare

Get $20 gift card from Amazon

Shipping Info:

Order now and get it on Friday July 04, 2025

Same day delivery FREE on San Diego area orders placed by 1.00 PM

Download TDS / Manual

Amount :	500 µg
Purification :	Purityâ‰¥98%
Content :	liquid (1 mg/ml)
Storage condition :	Store the product at 4°C for short term and at -20°C for long-term storage. Product is stable for 2 years at -20°C.


Alternative Name :	Resiquimod; S 28463; R848

Formula: C17H22N4O2

CAS#144875-48-9

MW: 314.4

Immune response modifier. Potent antitumor and antiviral compound. Stimulates antibody secretion and cytokine production. Used as adjuvant to increase the effectiveness of vaccines, potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-κB, NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I.Upregulator of the opioid growth factor receptor. Used in the treatment of skin lesions such as herpes simplex virus.

Solubility: Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate.

For Research Use Only. Not for use in diagnostic/therapeutics procedures.

1. Zhang K, Zakeri A, Alban T, Dong J, Ta HM, Zalavadia AH, Branicky A, Zhao H, Juric I, Husich H, Parthasarathy PB, Rupani A, Drazba JA, Chakraborty AA, Ching-Cheng Huang S, Chan T, Avril S, Wang LL.
VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.
Cell Rep. 2024 Jan 3;43(1):113661. doi: 10.1016/j.celrep.2023.113661. Epub ahead of print.
PMID: 38175754.

2. Comparative analyses for plant virus-based cancer immunotherapy drug development
Omole, Anthony O. et al.
Cell Biomaterials, Volume 0, Issue 0, 100095
https://www.cell.com/action/showCitFormats?doi=10.1016%2Fj.celbio.2025.100095&pii=S3050-5623%2825%2900086-8

There are currently no product reviews

Write a review on this product!